Mak J.W.Y.MENG-TZU WENGSHU-CHEN WEINg S.C.2021-06-152021-06-1520210815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087653615&doi=10.1111%2fjgh.15164&partnerID=40&md5=3d122651816093f58be512d48f78e1e9https://scholars.lib.ntu.edu.tw/handle/123456789/565637Background and Aim: It is unsure whether inflammatory bowel disease (IBD) is a risk factor for novel coronavirus infection (COVID-19). Methods: IBD patients were identified from population-based databases in Hong Kong and Taiwan from January 21, 2020, until April 15, 2020. Results: Total 2954 and 2554 IBD patients were identified in Hong Kong and Taiwan, respectively. None had COVID-19. Pooled analysis showed that 65.3%, 39.1%, 4.3%, and 12.8% IBD patients in Hong Kong and 75.8 %, 51.4 %, 26.1%, and 52.3 % in Taiwan were on 5-aminosalicylates, immunomodulators, corticosteroids, and biologics, respectively. Conclusion: There were no reported cases of COVID-19 infection amongst IBD patients in Hong Kong and Taiwan. IBD patients should continue their usual medications during the COVID-19 pandemic. ? 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, LtdenCOVID-19; epidemiology; inflammatory bowel disease[SDGs]SDG3adalimumab; biological product; corticosteroid; immunomodulating agent; infliximab; mercaptopurine; mesalazine; methotrexate; tacrolimus; ustekinumab; vedolizumab; adult; Article; cohort analysis; coronavirus disease 2019; disease registry; female; Hong Kong; human; inflammatory bowel disease; major clinical study; male; pandemic; population research; priority journal; retrospective study; risk factor; Taiwan; aged; complication; epidemiology; inflammatory bowel disease; middle aged; register; Adult; Aged; COVID-19; Female; Hong Kong; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Registries; Taiwanjournal article10.1111/jgh.15164325897982-s2.0-85087653615